Join Drs Tania Jain and Jeanne Palmer as they discuss their approach to transplant in myelofibrosis.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999597. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Myelofibrosis and Survival Prognostic Models: A Journey Between Past and Future https://pubmed.ncbi.nlm.nih.gov/36983189/

DIPSS plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status https://pubmed.ncbi.nlm.nih.gov/21149668/

Survival Following Allogeneic Transplant in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/32384540/

Posttransplant Cyclophosphamide vs Tacrolimus-based GVHD Prophylaxis: Lower Incidence of Relapse and Chronic GVHD https://pubmed.ncbi.nlm.nih.gov/37156098/

A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35130339/

Advances in Pharmacotherapy for Myelofibrosis: What Is the Current State of Play? https://pubmed.ncbi.nlm.nih.gov/38738513/

ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/38201581/

Superior Outcomes With Fludarabine-Busulfan (Flu/Bu) Based Conditioning for Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis - A Comparative Analysis by CIBMTR https://ashpublications.org/blood/article/138/Supplement%201/912/482649/Superior-Outcomes-with-Fludarabine-Busulfan-Flu-Bu

Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis With Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35158092/

Anti-T-Lymphocyte Globulin Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis After Matched Related or Unrelated Donor Transplantation https://pubmed.ncbi.nlm.nih.gov/38773281/

Donor Types and Outcomes of Transplantation in Myelofibrosis: A CIBMTR Study https://pubmed.ncbi.nlm.nih.gov/38916866/

Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/31288096/

Join Drs Tania Jain and Raajit Rampal as they discuss TP53, post-MPN AML, and high-risk MPNs in the context of myelofibrosis.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999596. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Primary Myelofibrosis https://emedicine.medscape.com/article/197954-overview

Myeloproliferative Neoplasms https://www.ncbi.nlm.nih.gov/books/NBK531464/

Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies https://pubmed.ncbi.nlm.nih.gov/36632576/

Updated Safety and Efficacy Data From the Phase 3 MANIFEST-2 Study of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients With Myelofibrosis https://meetings.asco.org/abstracts-presentations/231688

Next Generation Sequencing in MPNs. Lessons From the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses https://pubmed.ncbi.nlm.nih.gov/32781570/

The MDM2 Antagonist Idasanutlin in Patients With Polycythemia Vera: Results From a Single-Arm Phase 2 Study https://ashpublications.org/bloodadvances/article/6/4/1162/483223/The-MDM2-antagonist-idasanutlin-in-patients-with

Venetoclax With Azacitidine or Decitabine in Blast-Phase Myeloproliferative Neoplasm: A Multicenter Series of 32 Consecutive Cases https://pubmed.ncbi.nlm.nih.gov/33844862/

Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation Versus Nontransplantation Therapies in Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/33798769/

Genomic Analysis of Primary and Secondary Myelofibrosis Redefines the Prognostic Impact of ASXL1 Mutations: a FIM Study https://pubmed.ncbi.nlm.nih.gov/33666653/

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes https://pubmed.ncbi.nlm.nih.gov/27959731/

Safety and Efficacy of Combined Ruxolitinib and Decitabine in Accelerated and Blast-phase Myeloproliferative Neoplasms https://pubmed.ncbi.nlm.nih.gov/30563881/

Efficacy and Safety of Combination Therapies vs Monotherapy of Hypomethylating Agents in Accelerated or Blast Phase of Philadelphia Negative Myeloproliferative Neoplasms: a Systematic Review and Meta-analysis https://pubmed.ncbi.nlm.nih.gov/36644935/

Genomic and Functional Analysis of Leukemic Transformation of Myeloproliferative Neoplasms https://pubmed.ncbi.nlm.nih.gov/25516983/

BMP2/SMAD Pathway Activation in JAK2/p53-Mutant Megakaryocyte/Erythroid Progenitors Promotes Leukemic Transformation https://pubmed.ncbi.nlm.nih.gov/35421216/

Single-Cell Multi-omics Identifies Chronic Inflammation as a Driver of TP53-Mutant Leukemic Evolution https://pubmed.ncbi.nlm.nih.gov/37666991/

Join Drs Tania Jain and Lindsay Rein as they discuss the current treatment landscape and their approach to treating patients with myelofibrosis.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999595. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Primary Myelofibrosis https://emedicine.medscape.com/article/197954-overview

Myeloproliferative Neoplasms https://www.ncbi.nlm.nih.gov/books/NBK531464/

Acute Myeloid Leukemia (AML) Treatment Protocols https://emedicine.medscape.com/article/2004793-overview

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-Phase Myelofibrosis With an IDH2 Mutation https://clinicaltrials.gov/study/NCT04281498

Momelotinib Versus Danazol in Symptomatic Patients With Anaemia and Myelofibrosis (MOMENTUM): Results From an International, Double-Blind, Randomised, Controlled, Phase 3 Study https://pubmed.ncbi.nlm.nih.gov/36709073/

Pacritinib Is a Potent ACVR1 Inhibitor With Significant Anemia Benefit in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/37552106/

Safety and Efficacy of Luspatercept for the Treatment of Anemia in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/38820422/

Venetoclax With Azacitidine or Decitabine in Blast-Phase Myeloproliferative Neoplasm: A Multicenter Series of 32 Consecutive Cases https://pubmed.ncbi.nlm.nih.gov/33844862/

Interferon Therapy in Myelofibrosis: Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/32669244/